title: Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
abstract: We evaluated the efficacy of daunorubicin  (40 mg/m(2)/day for 5 days, 200 mg/m(2)/cycle) combined with standard dose of cytarabine (100 mg/m(2)/day for 7 days) for acute myelogenous leukemia patients aged 65-74 years as induction therapy. Complete remission (81.3%) was achieved in 13 of 16 patients following the therapeutic program. The median duration of recovering absolute neutolophilic counts over 1000/µl and platelet counts over 100 000/µl were 33 days and 27 days, respectively. None of the patients had any adverse cardiac complications or died during administration of the induction therapy. Patients achieving complete remission received post-remission therapy consisting of two regimens other than induction therapy. The 3-year disease-free and overall survival rates were 36.9 and 50.0%, respectively. Extending the total period of the daunorubicin therapy might be an alternative to increasing the daily dose of daunorubicin in the induction therapy for elderly patients who were candidates for receiving intensified chemotherapy.
authors.affiliation: Department of Clinical Oncology and Hematology, Jikei University Daisan Hospital, 4-11-1, Izumi-honcho, Komae-shi, Tokyo 201-8601, Japan. dobashi@jikei.ac.jp
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Dobashi
authors.forename: Noriko
authors.initials: N
authors.lastname: Usui
authors.forename: Shingo
authors.initials: S
authors.lastname: Yano
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yahagi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takei
authors.forename: Katsuki
authors.initials: K
authors.lastname: Sugiyama
authors.forename: Shinobu
authors.initials: S
authors.lastname: Takahara
authors.forename: Yoji
authors.initials: Y
authors.lastname: Ogasawara
authors.forename: Yuko
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Saito
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Keisuke
authors.initials: K
authors.lastname: Aiba
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D003561:Cytarabine; D003630:Daunorubicin